United States Assisted Reproductive Technology Market Report by Technology, End Use, States and Companies Analysis 2026-2034

United States Assisted Reproductive Technology Market Size & Forecast 2026-2034

The United States Assisted Reproductive Technology (ART) Market is anticipated to experience substantial growth, driven by rising infertility rates, increasing awareness of fertility treatments, delayed parenthood, and continuous advancements in reproductive technologies. The market is projected to grow from US$ 6.01 Billion in 2025 to US$ 9.31 Billion by 2034, registering a Compound Annual Growth Rate (CAGR) of 4.98% during the forecast period from 2026 to 2034. Expanding access to fertility services, growing acceptance of assisted reproduction, and increasing investments in fertility clinics are expected to further support market expansion across the United States.

United States Assisted Reproductive Technology Industry Overview

Assisted Reproductive Technology (ART) refers to a group of medical procedures used to help individuals and couples achieve pregnancy when natural conception is difficult or unsuccessful. ART includes treatments such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), embryo transfer, egg freezing, sperm donation, and fertility preservation techniques. These technologies involve handling eggs, sperm, or embryos outside the body to improve the chances of successful conception.

In the United States, ART has become increasingly popular due to rising infertility rates, delayed parenthood, changing lifestyle factors, and growing awareness of fertility treatment options. The technology is widely used by couples experiencing infertility, single parents by choice, and same-sex couples seeking to build families. Advances in reproductive medicine, improved success rates, and expanding fertility clinic networks have further boosted adoption across the country. United States is one of the world's largest markets for assisted reproductive technology, supported by strong healthcare infrastructure, ongoing research, and increasing acceptance of fertility treatments. As demand for family-building solutions continues to rise, ART remains a critical component of modern reproductive healthcare.

Launch of Moms.gov to Support Maternal and Family Health in the United States

In May 2026, the U.S. Department of Health and Human Services (HHS) launched Moms.gov, a dedicated online platform designed to provide information, resources, and guidance aimed at improving the health and well-being of mothers, infants, and families. The website serves as a centralized resource for expectant parents, particularly those facing challenging or unplanned pregnancies, by offering access to educational materials, healthcare resources, nutritional information, pregnancy-related support services, and programs such as Trump Accounts.

The homepage emphasizes the platform’s mission of supporting parents during pregnancy and promoting healthier outcomes for mothers and children across the United States. The website highlights resources intended to help families navigate pregnancy-related decisions while accessing available support services.

A key feature of Moms.gov is its connection to Pregnancy Centers, which offer services such as pregnancy testing, counseling, and assistance with essential baby supplies, including diapers and other necessities at no cost. The platform directs users to Option Line, an external resource operated by Heartbeat International, a nonprofit organization that provides pregnancy support and counseling services.

Additionally, Moms.gov prominently features information about Federally Qualified Health Centers (FQHCs), which offer comprehensive healthcare services including prenatal care, maternity care, primary healthcare, and preventive services. Users can access the Health Resources and Services Administration (HRSA) directory through the website to locate nearby FQHC facilities and obtain affordable healthcare support during pregnancy and beyond.

Assisted Reproductive Technology (ART) Launches in the United States

Date Product/Technology Launch Company Description

Jul-24 EmbryoView Pro Hamilton Thorne

AI-powered embryo monitoring and assessment system designed to improve embryo selection accuracy and IVF outcomes.

19-Mar-24 CryoLink TMRW Life Sciences

Digital specimen management platform enabling fertility clinics to modernize frozen egg and embryo storage workflows.

Oct-24 Embryo Assist Integration Alife Health & Hamilton Thorne AI-powered embryo selection software integrated into Hamilton Thorne laser systems for IVF laboratories.

21-Oct-24 Integrated IVF Specimen Transport Platform TMRW Life Sciences & Cryoport Systems Partnership launch providing secure transport, storage, and management solutions for frozen eggs, embryos, and sperm.

Aug-24 Cryo Management Technology Expansion in Alabama TMRW Life Sciences

Deployment of FDA-cleared automated fertility specimen storage technology in Alabama fertility clinics.

Jun-24 Expanded Cryostorage Network TMRW Life Sciences

Launch of additional state-of-the-art cryostorage facilities supporting fertility clinics across the United States.

2024 AI-Enhanced Clinical Decision Support Platform Alife Health

Advanced IVF decision-support software utilizing patient and embryo data to optimize treatment protocols and embryo selection.

2024 Automation in ART Laboratory Solutions Hamilton Thorne

New automation-focused technologies introduced to improve IVF laboratory workflows, embryo handling, and operational efficiency.

2024 AI-Based Embryo Euploidy Screening Tool AIVF

AI-driven embryo evaluation platform designed to assess genetic quality using time-lapse embryo imaging.

2023-2024 U.S. Rollout CryoRobot Select TMRW Life Sciences

FDA-cleared automated robotic storage platform for frozen eggs, embryos, and sperm, increasingly adopted by U.S. fertility clinics.

Growth Drivers for the United States Assisted Reproductive Technology Market

Increasing Adoption of Preimplantation Genetic Testing (PGT)

The growing use of Preimplantation Genetic Testing (PGT) is emerging as a major driver of growth in the United States Assisted Reproductive Technology (ART) market. PGT enables fertility specialists to evaluate embryos for genetic abnormalities before implantation, improving the likelihood of a successful pregnancy and reducing the risk of inherited disorders. Advanced technologies such as Next-Generation Sequencing (NGS) provide highly accurate genetic screening, allowing clinicians to identify chromosomal abnormalities with greater precision. As a result, patients can make more informed reproductive decisions and select embryos with the highest implantation potential. The demand for PGT-A, which screens embryos for aneuploidy, has increased significantly among older women, couples experiencing recurrent pregnancy loss, and individuals with multiple unsuccessful IVF attempts. This growing preference reflects the broader trend toward personalized and precision medicine in reproductive healthcare. By improving embryo selection, increasing implantation success rates, and enhancing live birth outcomes, genetic testing technologies are becoming an integral component of modern fertility treatments across the United States.

Advancements in Artificial Intelligence and IVF Automation

Artificial intelligence (AI) and automation technologies are significantly transforming the assisted reproductive technology landscape by improving the efficiency, accuracy, and consistency of fertility treatments. AI-powered systems are increasingly being integrated into IVF laboratories to assist with embryo assessment, patient management, and treatment optimization. Advanced imaging technologies, including time-lapse embryo monitoring systems, allow continuous observation of embryo development without disturbing the culture environment. These innovations help embryologists identify the most viable embryos for transfer, leading to improved pregnancy outcomes. Automation solutions are also streamlining laboratory operations by reducing manual handling and minimizing the potential for human error in embryo storage and management processes. Furthermore, AI-driven platforms can analyze large volumes of patient data to generate personalized treatment recommendations, helping fertility specialists optimize clinical outcomes. In July 2024, Hamilton Thorne Ltd. introduced EmbryoView Pro, an advanced embryo monitoring system utilizing AI-based analysis for real-time embryo evaluation. Such innovations continue to accelerate technological progress and strengthen the growth prospects of the ART market.

Rising Demand for Fertility Preservation and Egg Freezing

The increasing popularity of fertility preservation and egg freezing is playing a crucial role in driving growth within the United States ART market. Many women are choosing to delay parenthood due to career aspirations, educational goals, financial considerations, or personal preferences. As awareness of age-related fertility decline grows, more individuals are exploring fertility preservation options to maintain future reproductive flexibility. Significant improvements in vitrification technology have enhanced egg freezing success rates by increasing the survival of eggs during freezing and thawing procedures. This has improved confidence in fertility preservation as a viable long-term reproductive strategy. In addition, several major employers now offer fertility benefits that include egg freezing as part of employee healthcare packages, making these services more accessible. Fertility clinics are also actively promoting preservation solutions as a proactive approach to reproductive planning. This trend reflects evolving social attitudes toward family planning and the growing acceptance of advanced reproductive technologies that provide individuals with greater control over their fertility choices.

Challenges in the United States Assisted Reproductive Technology Market

High Cost of Fertility Treatments

The high cost associated with fertility treatments remains one of the most significant challenges facing the United States assisted reproductive technology market. Procedures such as in vitro fertilization (IVF) require substantial financial investment, with treatment costs often ranging from thousands to tens of thousands of dollars per cycle. Since many patients require multiple treatment cycles to achieve a successful pregnancy, the overall financial burden can become considerable. Additional expenses related to fertility medications, genetic testing, embryo storage, and specialized laboratory procedures further increase the total cost of care. Although demand for fertility services continues to grow, limited insurance coverage remains a major barrier for many individuals and families. In numerous cases, patients must pay out of pocket for a significant portion of treatment expenses. As a result, affordability concerns can delay or prevent access to fertility services, particularly among middle-income and lower-income populations. This cost challenge continues to contribute to disparities in access to reproductive healthcare across the country.

Regulatory and Compliance Challenges

Regulatory complexities present a notable challenge for the growth and standardization of the United States assisted reproductive technology market. Unlike many healthcare sectors that operate under comprehensive federal oversight, the ART industry is governed through a combination of federal guidelines, professional standards, and varying state-level regulations. This fragmented regulatory framework can create inconsistencies in treatment practices, quality standards, patient protections, and reporting requirements across fertility clinics. Differences in state laws regarding embryo handling, fertility coverage, donor regulations, and reproductive rights further complicate the operational environment for providers and patients. Additionally, varying reporting practices and limited enforcement mechanisms can affect transparency and make it difficult for patients to compare treatment outcomes across clinics. Compliance with evolving legal, ethical, and medical standards also requires significant administrative and financial resources. These regulatory uncertainties can slow innovation, increase operational complexity, and create challenges for healthcare providers seeking to deliver consistent, high-quality reproductive care nationwide.

United States In Vitro Fertilization (IVF) Market

The United States In Vitro Fertilization (IVF) Market continues to expand due to increasing infertility rates, delayed parenthood, and growing awareness of reproductive health solutions. IVF remains the most widely used assisted reproductive procedure, helping individuals and couples overcome infertility challenges and achieve successful pregnancies. Technological advancements in embryo culture systems, genetic testing, cryopreservation techniques, and laboratory automation have significantly improved treatment outcomes and success rates. Growing acceptance of fertility treatments among diverse patient groups, including single parents and same-sex couples, is further contributing to market growth. Additionally, rising investments in fertility clinics, expanding healthcare infrastructure, and increasing employer-sponsored fertility benefits are making IVF services more accessible. Fertility specialists are increasingly utilizing personalized treatment plans and advanced diagnostic tools to optimize patient outcomes. As reproductive technologies continue to evolve and patient awareness increases, the United States IVF market is expected to maintain strong growth and remain a critical segment within reproductive healthcare services.

United States Frozen Embryo Transfer (FET) Market

The United States Frozen Embryo Transfer (FET) Market is experiencing substantial growth due to advancements in embryo freezing technologies and increasing preference for flexible fertility treatment options. Frozen embryo transfer involves thawing previously cryopreserved embryos and transferring them into the uterus during a carefully monitored treatment cycle. Improvements in vitrification techniques have significantly enhanced embryo survival rates, resulting in pregnancy outcomes comparable to or better than fresh embryo transfers. FET procedures provide greater flexibility for patients and physicians by allowing optimal timing for embryo transfer while reducing physical stress associated with ovarian stimulation cycles. The growing use of preimplantation genetic testing has also contributed to higher adoption of frozen embryo transfers, as embryos can be screened before implantation. Additionally, fertility preservation trends and increasing use of donor eggs and embryos are supporting market expansion. As clinical success rates continue to improve, frozen embryo transfer is becoming an increasingly important component of fertility treatment strategies across the United States.

United States Assisted Reproductive Technology Market

The United States Assisted Reproductive Technology (ART) Market is witnessing robust growth driven by increasing infertility prevalence, delayed family planning, and rising acceptance of fertility treatments. ART encompasses a broad range of reproductive procedures, including IVF, intracytoplasmic sperm injection (ICSI), egg freezing, embryo freezing, donor programs, and fertility preservation services. Continuous advancements in reproductive medicine, artificial intelligence-assisted embryo selection, genetic testing, and laboratory automation are improving treatment success rates and enhancing patient experiences. Growing awareness of fertility health and expanding access to fertility clinics have increased demand across diverse patient populations. Employer-sponsored fertility benefits and broader insurance coverage in certain states are also helping improve treatment accessibility. Furthermore, increasing research activities and investment in reproductive technologies are fostering innovation throughout the industry. As social attitudes toward assisted reproduction continue to evolve, the United States ART market is expected to remain one of the most advanced and rapidly growing fertility treatment markets globally.

United States Assisted Reproductive Technology Market by Fertility Preservation Services

The fertility preservation segment represents a rapidly growing area within the United States Assisted Reproductive Technology Market. Increasing numbers of individuals are choosing to preserve their reproductive potential through egg freezing, embryo freezing, and sperm preservation techniques. Factors such as delayed parenthood, career planning, medical treatments affecting fertility, and growing awareness of age-related fertility decline are driving demand for preservation services. Technological improvements in cryopreservation and vitrification have enhanced long-term storage outcomes and increased confidence in future fertility options. Healthcare providers and fertility clinics are actively promoting fertility preservation as a proactive reproductive strategy for both medical and elective purposes. Additionally, employer-sponsored fertility benefits and educational initiatives have increased awareness and accessibility of these services. As more individuals seek flexibility in family planning decisions, fertility preservation is becoming an integral component of reproductive healthcare. This trend is expected to support sustained growth within the broader United States assisted reproductive technology market over the coming years.

California Assisted Reproductive Technology Market

California represents one of the largest and most developed assisted reproductive technology (ART) markets in the United States. The state’s strong healthcare infrastructure, high concentration of fertility clinics, and early adoption of advanced reproductive technologies have contributed significantly to market growth. Increasing awareness of fertility treatments, delayed parenthood, and growing acceptance of alternative family-building options are driving demand for ART services across the state. California is also home to numerous biotechnology companies and research institutions that support continuous innovation in reproductive medicine. Advanced procedures such as in vitro fertilization (IVF), egg freezing, embryo preservation, and genetic testing are widely available and frequently utilized. The presence of employer-sponsored fertility benefits among major technology and healthcare companies further enhances accessibility to treatment. Additionally, California’s diverse population and progressive healthcare environment encourage broader adoption of fertility services. These factors position California as a leading regional market for assisted reproductive technology and fertility care innovation.

Texas Assisted Reproductive Technology Market

The Texas Assisted Reproductive Technology Market is experiencing strong growth due to increasing infertility awareness, population expansion, and rising demand for fertility treatments. The state’s large and growing population creates substantial opportunities for fertility clinics and reproductive healthcare providers. Assisted reproductive technologies such as IVF, intracytoplasmic sperm injection (ICSI), egg freezing, and fertility preservation services are becoming increasingly popular among individuals and couples seeking family-building solutions. Growing investments in healthcare infrastructure and fertility clinic expansion are improving access to advanced reproductive care throughout urban and suburban areas. Technological advancements in embryo selection, cryopreservation, and genetic screening are contributing to improved treatment outcomes and patient satisfaction. Rising awareness regarding age-related fertility decline and reproductive health management is also encouraging more individuals to seek professional fertility assistance. Despite challenges related to treatment affordability, Texas continues to emerge as an important market for ART services due to its expanding healthcare sector and growing patient population.

New York Assisted Reproductive Technology Market

The New York Assisted Reproductive Technology Market is characterized by high demand for fertility services, advanced medical facilities, and a strong focus on reproductive healthcare innovation. The state benefits from a well-established network of fertility clinics, academic medical centers, and specialized reproductive health providers that offer comprehensive ART services. Delayed parenthood, increasing infertility rates, and greater awareness of fertility preservation options are key factors supporting market growth. New York has witnessed growing demand for procedures such as IVF, embryo freezing, egg freezing, donor-assisted reproduction, and preimplantation genetic testing. The state’s highly educated population and access to specialized healthcare services contribute to greater utilization of advanced reproductive technologies. In addition, expanding insurance coverage for fertility treatments in certain healthcare plans has improved patient access to reproductive services. Continuous technological advancements and ongoing investments in fertility research further strengthen New York’s position as one of the most significant assisted reproductive technology markets in the country.

Florida Assisted Reproductive Technology Market

The Florida Assisted Reproductive Technology Market is growing steadily due to increasing awareness of infertility treatments, expanding healthcare infrastructure, and rising demand for fertility preservation services. The state’s large population, including a significant number of individuals delaying parenthood, creates favorable conditions for market expansion. Fertility clinics across Florida are increasingly offering advanced reproductive procedures such as IVF, ICSI, egg freezing, embryo freezing, and genetic testing to meet evolving patient needs. Improvements in reproductive technologies and laboratory capabilities have enhanced treatment success rates, encouraging greater adoption of ART services. Florida’s reputation as a healthcare destination also attracts patients seeking specialized fertility treatments from other regions. Additionally, growing awareness of fertility preservation among younger individuals and cancer patients is contributing to market growth. Increasing investments in reproductive healthcare facilities, combined with advancements in personalized fertility treatments, are expected to further support the expansion of the Florida assisted reproductive technology market in the coming years.

Research Methodology of "7. U.S. Assisted Reproductive Technology Market

[external URL]

1. Market Definition

ART can mean the clinical services/procedures delivered by fertility clinics, or a broader ecosystem including fertility drugs, PGT testing, donor services, cryopreservation / storage, equipment and consumables. For a market-research report, I recommend estimating the ART services market first, then presenting drugs/devices/testing as separate adjacent markets. We have excluded fertility drugs, fertility insurance administration, neonatal care and ART equipment from the core market unless the report specifically defines the market broadly.

2. Number of ART cycles This is the strongest part of the U.S. market model because U.S. ART activity is tracked by CDC and SART. Approach

• 2024 = latest SART/ASRM activity data
• 2022 = CDC benchmark / validation year

3. Market by procedure

• ART Market Revenue = ∑ (Number of Procedures × Average Revenue per Procedure)
• IVF Revenue = IVF Cycles × Average IVF Revenue / Cycle
• FET Revenue = FET Transfers × Average FET Revenue / Transfer
• Egg Freezing Revenue = Egg Freezing Cycles × Average Revenue / Cycle
• Storage Revenue = Number of Stored Samples × Annual Storage Fee
• Total ART Market = IVF + FET + Donor Egg + Cryopreservation + Storage + PGT + Other

4. Used CDC/SART data to calculate procedure volumes: CDC's NASS provides datasets covering:

• ART services and clinic profiles
• patient and cycle characteristics
• ART success rates
• summary data

Step 1 - Number of clinics

• → State
• → Clinic
• → Ownership
• → Annual ART cycles

Step 2 - Number of cycles

• → Own-egg IVF
• → Donor-egg IVF
• → Frozen embryo transfers
• → Egg freezing
• → Embryo banking
• → Other procedures

Step 3 - Revenue per procedure

• → Clinic quoted price
• → Regional price adjustment
• → Insurance/self-pay adjustment
• → Add-ons

5. State Segmentation:

• State ART Market = State ART Cycles × State Average Revenue / Cycle

6. Separate insured and self-pay revenue

• Insurance coverage
• Employer fertility benefits
• State mandates
• Self-pay
• Financing programs
• Discount packages
• Multi-cycle packages
• Revenue = (Self Pay Patients × Self Pay ASP) + (Insured Patients × Insurer Reimbursement)

7. Fertility Preservation

• Egg freezing is becoming an important component of the ART ecosystem.
• Egg Freezing Market = Number of Egg Freezing Cycles × Average Procedure Fee
• Annual Storage Revenue = Cumulative Stored Eggs × Annual Storage Fee

8. PGT as an ancillary revenue stream

• Included inside ART market revenue, or
• Reported as a separate ancillary market.
• PGT Revenue = Number of IVF Cycles using PGT × Average PGT Revenue / Cycle

9. Success rates as a secondary validation variable

• Live Births = ART Cycles × Live Birth Rate

10. Cross Checking the Approaches

• Approach 1 - Procedure × ASP: ART Market = ∑ Procedures × ASP
• Approach 2 - Clinic revenue: Number of ART Clinics × Average ART Revenue / Clinic
• Large fertility groups
• Hospital-affiliated centers
• Independent clinics
• Academic centers

Approach 3 - Patient expenditure

• ART Patients × Average Annual ART Spend / Patient Can we make this in paragraph form and bullet-pointed list

Research Methodology of Medical Writing Market

1. Medical Writing Market Definition

The Medical Writing Market is estimated as a service-revenue market, based on the volume of medical and scientific documents generated by pharmaceutical, biotechnology, medical-device, and healthcare organizations, the proportion of these activities outsourced to external service providers, and the average fee charged per assignment. The market therefore captures the commercial value of professional medical writing services performed by specialized agencies, CROs, freelance medical writers, and other service providers. For this report, Medical Writing Services are defined to include the following major service segments:

• Clinical Writing
• Regulatory Writing
• Scientific and Publication Writing
• Medical Communications
• Pharmacovigilance / Safety Writing
• Medico-Marketing Writing
• Medical-Device Writing

2. Market Sizing Formula
The Medical Writing Market is estimated using a document/project-based approach, where the number of documents or projects generated is multiplied by the average fee per document and the share of work outsourced to third-party providers. The basic formula is: Medical Writing Market Size = Σ (Number of Documents × Average Fee per Document × Outsourcing Penetration). The same methodology is applied separately across the major market segments:

• Clinical Writing
• Regulatory Writing
• Scientific / Publication Writing
• Medical Communications
• Pharmacovigilance / Safety Writing
• Medico-Marketing Writing
• Medical-Device Writing

3. Bottom-Up Methodology
The bottom-up methodology begins by estimating the addressable customer universe and assessing the medical writing requirements generated by each customer group. The analysis considers the number and type of organizations, their development activities, the volume of documentation required, outsourcing practices, and prevailing pricing levels.

A. Pharmaceutical Companies:

• Large pharmaceutical companies
• Mid-sized pharmaceutical companies
• Specialty pharmaceutical companies
• Generic pharmaceutical companies
• Emerging pharmaceutical companies

B. Biotechnology Companies:

• Clinical-stage biotechnology companies
• Commercial-stage biotechnology companies
• Gene and cell therapy companies
• Rare-disease biotechnology companies
• Oncology-focused biotechnology companies
• Immunology and other therapeutic-area companies

C. Medical-Device Companies

• Class II and Class III medical devices
• Diagnostics and in-vitro diagnostics
• Digital health products
• Combination products
• Other regulated medical technologies

D. CROs and Other Healthcare Organizations

• Contract Research Organizations (CROs)
• Medical communications agencies
• Academic and research organizations
• Healthcare institutions
• Healthcare consulting firms
• Other organizations involved in clinical, scientific, or regulatory activities

4. Estimation of Number of Projects
The next stage is to estimate the number of medical writing projects generated by the addressable customer base. For clinical writing, demand is linked primarily to the number of active clinical development programs and clinical studies. A simplified calculation is: Clinical Writing Demand = Number of Active Clinical Programs × Studies per Program × Writing Documents per Study

The same principle can be adapted for other writing categories by identifying the relevant project or documentation drivers. For example, regulatory writing can be linked to the number of regulatory submissions, while publication writing can be linked to the number of clinical studies and research outputs.

5. Document-Level Demand Model
Medical writing demand is estimated at the individual document level because each clinical, regulatory, or scientific activity can generate multiple writing requirements throughout the development lifecycle. Clinical Writing: For each clinical trial, documents are considered across three major stages:

Before the Trial

• Clinical trial protocol
• Protocol amendments
• Investigator's Brochure
• Informed-consent documents
• Trial-related summaries and supporting documents

During the Trial

• Safety narratives
• Patient-facing documents
• Clinical updates
• Other trial-management documentation

After the Trial

• Clinical Study Report (CSR)
• Clinical summaries
• Submission-related documents
• Scientific publications and manuscripts

Regulatory Writing
Regulatory writing demand is estimated based on the number of regulatory submissions and the number of documents required for each submission. The basic formula is: Regulatory Writing Demand = Number of Regulatory Submissions × Documents per Submission. The model can further differentiate submissions by regulatory pathway, product type, geography, and complexity where sufficient data are available.

Other Writing Categories
A similar project- and document-based methodology is applied to scientific/publication writing, medical communications, pharmacovigilance writing, medico-marketing writing, and medical-device writing by identifying the relevant demand drivers and associated documentation requirements.

6. Estimation of Average Pricing
Once the volume of documents and projects has been estimated, the next step is to determine the average market price per document or assignment. Pricing varies significantly depending on document complexity, therapeutic area, regulatory requirements, turnaround time, writer expertise, and whether the work is performed by a specialized agency, CRO, freelance writer, or in-house team. Key document and service categories considered for pricing include:

• Abstracts
• Posters
• Manuscripts
• Clinical trial protocols
• Investigator's Brochures
• Clinical Study Reports (CSRs)
• Regulatory documents
• Medical communications projects
• Pharmacovigilance / safety documents
• Medical-device documentation

Average pricing can be established through a combination of primary interviews, industry benchmarks, vendor quotations, and secondary research. Alternative FTE-Based Pricing Model. For engagements delivered through dedicated medical-writing teams, pricing can also be estimated using an FTE-based approach: Annual Medical Writing Revenue = Annual Writer Cost × Number of Writers × Outsourcing / Service Markup. This approach is particularly relevant for long-term managed-service, dedicated-resource, and FTE-based outsourcing contracts.

7. Outsourcing Penetration
Not all medical writing activities are outsourced. Pharmaceutical, biotechnology, medical-device, and healthcare organizations may maintain internal medical writing teams while outsourcing specialized, high-volume, or project-based activities. Therefore, the total potential medical writing spend is adjusted using an outsourcing penetration rate: Outsourced Medical Writing Market = Total Medical Writing Spend × Outsourcing Rate. Outsourcing penetration is estimated using secondary research and primary interviews with relevant industry stakeholders, including:

• Heads of Medical Writing
• Procurement executives
• Clinical development executives
• Regulatory affairs professionals
• CRO executives
• Medical communications agencies
• Independent medical writers

8. Top-Down Methodology for Cross-Checking

Approach A - Healthcare R&D Expenditure:

The first approach estimates medical writing expenditure as a proportion of pharmaceutical and biotechnology R&D spending. Medical Writing Market = Pharma / Biotech R&D Expenditure × Medical Writing Spend as % of R&D × Outsourcing Percentage. This approach provides an indication of the potential medical writing spend relative to the overall investment in research and development.

Approach B - CRO Outsourcing
The second approach uses the broader CRO market as a benchmark and estimates the proportion attributable to medical writing services. Medical Writing Market = CRO Market Size × Medical Writing Share of CRO Services. The resulting estimate is compared against the bottom-up model to assess overall market reasonableness.

9. Alternative FTE-Based Market Sizing Model
An additional methodology estimates market size based on the number of medical writers working through outsourced service arrangements. The formula is: Medical Writing Market = Number of Outsourced Medical Writers × Average Annual Revenue per Writer. The number of outsourced writers can be estimated by analyzing employment structures, outsourcing contracts, dedicated-resource models, CRO staffing data, and interviews with service providers. The FTE-based model is particularly useful for markets where medical writing is commonly delivered through dedicated teams or resource-augmentation contracts rather than individual document assignments.

10. Final Market Size and Reconciliation
Model 1 - Project / Document-Based Model: Market Size = Number of Documents or Projects × Average Fee. This methodology provides a detailed view of market demand by document type and service category. Model 2 - Customer-Based Model: Market Size = Number of Addressable Customers × Average Annual Medical-Writing Expenditure per Customer. This approach captures the spending behavior of pharmaceutical, biotechnology, medical-device, CRO, and other healthcare organizations. Model 3 - FTE-Based Model: Market Size = Number of Outsourced Medical Writers × Annual Revenue per Writer. This approach provides a workforce- and outsourcing-based perspective of the market.

Final Market Size
The final market size is determined through a weighted reconciliation of the three approaches, with greater weight assigned to the methodology considered most reliable based on data availability and market characteristics. Final Medical Writing Market Size = Weighted Average / Reconciled Estimate of Project-Based, Customer-Based, and FTE-Based Models. The three approaches are also used as cross-checks to ensure that the final estimate is commercially realistic and internally consistent across customer segments, document volumes, pricing, and outsourcing penetration.

United States Assisted Reproductive Technology Market Segments:

Technology

• In Vitro Fertilization (IVF)
• Artificial Insemination (AI-IUI)
• Frozen Embryo Transfer (FET)
• Others

End Use

• Hospitals
• Fertility Clinics
• Other end users/providers

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Cosmos Biomedical Ltd.
• Microm U.K. Ltd.
• CooperSurgical, Inc.
• FUJIFILM Irvine Scientific, Inc.
• Cryolab Ltd.
• Vitrolife AB
• Merck KGaA
• Ferring B.V.